Verification evidence is still being completed.
PDF / print export
AnaCardio
Stockholm, Sweden
- Verified lead
- Patrik Stromberg
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Heart Failure, Cardiovascular Therapeutics, Clinical Development, Contractile Agents, and Biopharma
- Review cycle
- May 2026
- Full address
- AnaCardio AB, Fogdevreten 2, 171 65 Stockholm, Sweden
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official AnaCardio contact page confirming the Stockholm address.
- Editorial note
- AnaCardio is published because official company materials confirm current leadership, Stockholm operating address, and a clear heart-failure therapeutics platform.
Heart Failure, Cardiovascular Therapeutics, Clinical Development, Contractile Agents, and Biopharma
Official leadership disclosure, Official Stockholm address disclosure, Clinical-stage therapeutics platform claim
AnaCardio is published because official company materials confirm current leadership, Stockholm operating address, and a clear heart-failure therapeutics platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Stockholm, Sweden
AnaCardio
Heart Failure, Cardiovascular Therapeutics, Clinical Development, Contractile Agents, and Biopharma · Clinical-stage therapeutics platform
AnaCardio runs cardiovascular drug development, clinical program execution, and heart failure platform development in Stockholm, Sweden.
- Lead
- Patrik Stromberg (verified ↗)
- Address
- AnaCardio AB, Fogdevreten 2, 171 65 Stockholm, Sweden (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Cardiovascular Drug Development · Clinical Program Execution · Heart Failure Platform Development
- Founded
- 2017
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Patrik Stromberg
CEO
Full addressAnaCardio AB, Fogdevreten 2, 171 65 Stockholm, Sweden
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage therapeutics platform
Stockholm, Sweden. Heart Failure, Cardiovascular Therapeutics, Clinical Development, Contractile Agents, and Biopharma. Review completed on 22 Mar 2026.
Swedish corporate and clinical-development oversight
Official leadership disclosure, Official Stockholm address disclosure, Clinical-stage therapeutics platform claim
Heart Failure, Cardiovascular Therapeutics, Clinical Development, Contractile Agents, and Biopharma
AnaCardio is published because official company materials confirm current leadership, Stockholm operating address, and a clear heart-failure therapeutics platform.
Editorial note
AnaCardio is published because official company materials confirm current leadership, Stockholm operating address, and a clear heart-failure therapeutics platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Cardiovascular Drug Development
Clinical Program Execution
Heart Failure Platform Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Cardiovascular R&D systems
Program management infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is AnaCardio located?
- AnaCardio operates from AnaCardio AB, Fogdevreten 2, 171 65 Stockholm, Sweden, Stockholm, Sweden.
- Who runs AnaCardio?
- AnaCardio is led by Patrik Stromberg, CEO. Verified 22 Mar 2026.
- What does AnaCardio do?
- AnaCardio runs cardiovascular drug development, clinical program execution, and heart failure platform development in Stockholm, Sweden. Core capabilities: Cardiovascular Drug Development, Clinical Program Execution, Heart Failure Platform Development.
Editorial context
Related technical briefs
Briefs that name Stockholm as a covered market or city.